Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates

Company Performance - Agios Pharmaceuticals reported a quarterly loss of $1.45 per share, better than the Zacks Consensus Estimate of a loss of $1.64, and compared to a loss of $1.47 per share a year ago, indicating an earnings surprise of 11.59% [1] - The company posted revenues of $8.19 million for the quarter ended March 2024, missing the Zacks Consensus Estimate by 2.56%, and showing an increase from $5.61 million in the same quarter last year [1] - Over the last four quarters, Agios has surpassed consensus EPS estimates three times but has topped consensus revenue estimates only once [1] Stock Performance - Agios Pharmaceuticals shares have increased approximately 51.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 5.2% [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$1.63 on revenues of $9.88 million, and for the current fiscal year, it is -$5.29 on revenues of $81.43 million [4] - The estimate revisions trend for Agios Pharmaceuticals is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [4] Industry Context - The Medical - Products industry, to which Agios belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting potential challenges for stocks within this sector [5] - Another company in the same industry, biote Corp., is expected to report quarterly earnings of $0.05 per share, reflecting a year-over-year change of -94.7%, with revenues anticipated to be $47.09 million, up 5% from the previous year [5][6]